Pocenbrodib

CellCentric has raised $120 million in Series C funding to advance inobrodib, a first-in-class oral p300/CBP inhibitor for multiple myeloma treatment.

Pathos AI secured $365 million in Series D financing, reaching a post-money valuation of $1.6 billion to expand its AI-enabled platform for oncology drug development.

Tempus AI has announced strategic collaborations with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology, with agreements totaling $200 million in data licensing and model development fees.

Pathos AI has dosed the first patient in a Phase 1b/2a trial evaluating pocenbrodib, a CBP/p300 inhibitor, alone and in combination with established therapies for metastatic castration-resistant prostate cancer.

Pathos AI closed an oversubscribed $62M Series C round, led by NEA, to expand its AI-powered drug development platform and advance its precision oncology therapeutics.